Our Team
Our success is driven by a world-class team of professionals. With seasoned management and a board with extensive experience in both Big Pharma and early-stage biotech, we are well-equipped to navigate the complexities of drug development and generate substantial value for all stakeholders.
The scientific advisory board for our first indication is made up of renowned scientists and clinicians, namely Prof. Roger Stupp (Northwestern), Prof. Mitch Berger (UCSF), Prof. Nicolas de Tribolet (UNIGE), Prof. Ariel Ruiz i Altaba (UNIGE) and Prof. Pierre Magistretti (EPFL).
Management team
Alan Cookson, PHD
Andrew Galazka, MD
Lionel Brodard
Marc Criton, PHD
Benedicte Fauvel, PHD
Marc Bonneville, PhD
BOARD OF DIRECTORS
Andrew Galazka, MD
Elsy Boglioli
Alexandre LeBeaut, MD
Julie Puype
Eric Falcand
WORLD CLASS GBM CLINICAL & SCIENTIFIC ADVISORY BOARD
Prof. Roger Stupp
Andrew Galazka, MD
Prof. Mitchel Berger
Prof. Nicolas de Tribolet
Prof. Ariel Ruiz i Altaba
Prof. Pierre Magistretti
PLATFORM SCIENTIFIC FOUNDERSā
Martin Villalba
Pierre Martineau, PHD
Javier Hernandez, PHD
Bruno Robert, PhD
Prof. Christian Jorgensen
- MedXCell
Cytea bio - a pipeline company of MedxcellĀ
CYTEA BIO is a pipeline company of MedXCell, a Swiss venture builder. CYTEA BIO has been founded and financed by MedXCell, gaining access to crucial skills to advance its programs. CYTEA BIO Ā is now in the process of raising its first external funding.
